文献速递艾滋病与性传播感染

现代蛋白酶抑制剂使用与HIV感染者新发慢性肾病风险:D:A:D研究

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
PubMed 文献 · J Infect Dis · 2019-01-01

基于D:A:D队列随访至2016年2月1日,采用校正泊松回归分析HIV感染者使用利托那韦增效阿扎那韦(ATV/r)或达芦那韦(DRV/r)与新发慢性肾病(CKD)的关联。

要点

  • ATV/r累积暴露越长,CKD发生率逐渐升高
  • DRV/r使用与新发CKD无显著关联
  • HIV感染者使用ATV/r时需关注肾功能监测

核心结论

  • ATV/r使用与CKD风险显著相关且随暴露时间增加而升高,DRV/r使用未显示显著关联。

研究设计与样本

  • D:A:D研究队列随访至CKD发生、末次访视后6个月或2016年2月1日,采用校正泊松回归分析。

主要发现

  • CKD发生率为10.0/1000人年(95%CI 9.5-10.4),随ATV/r暴露增加逐渐升高,DRV/r关系不明确。

临床怎么用

  • HIV感染者选用蛋白酶抑制剂时,应结合CKD风险权衡ATV/r与DRV/r,ATV/r使用期间加强肾功能监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD. CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ryom L, Dilling Lundgren J, Reiss P, et al. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019. PMID: 31504669. doi:10.1093/infdis/jiz369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。